Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Merdury Biopharmaceutical Corporation (6932) Financial Statements

Merdury Biopharmaceutical Corporation Financial Overview

Merdury Biopharmaceutical Corporation's market cap is currently NT$2.26B. The company's EPS TTM is NT$-0.12; its P/E ratio is -44.17; Merdury Biopharmaceutical Corporation has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.

Financial overview
Dec 25Dec 24Dec 23Dec 22Dec 21
Income Statement
Total RevenueNT$ 0.00NT$ 4.96MNT$ 1.03MNT$ 2.68MNT$ 0.00
Gross ProfitNT$ -11.64MNT$ 4.18MNT$ 592.00KNT$ 1.17MNT$ -972.00K
Operating IncomeNT$ -68.55MNT$ -54.04MNT$ -45.69MNT$ -30.85MNT$ -5.30M
EBITDANT$ -56.91MNT$ -42.27MNT$ -39.03MNT$ -28.10MNT$ -4.33M
Net IncomeNT$ -67.23MNT$ -50.57MNT$ -43.82MNT$ -31.25MNT$ -5.31M
Balance Sheet
Cash & Short-Term InvestmentsNT$ 163.77MNT$ 230.81MNT$ 329.07MNT$ 140.64MNT$ 2.56M
Total AssetsNT$ 278.39MNT$ 353.20MNT$ 438.07MNT$ 229.93MNT$ 13.38M
Total DebtNT$ 41.79MNT$ 47.51MNT$ 42.35MNT$ 43.42MNT$ 2.01M
Net DebtNT$ -11.38MNT$ -20.50MNT$ -1.95MNT$ 11.49MNT$ -550.00K
Total LiabilitiesNT$ 58.72MNT$ 62.93MNT$ 49.72MNT$ 49.60MNT$ 2.92M
Stockholders' EquityNT$ 219.67MNT$ 290.27MNT$ 388.35MNT$ 180.33MNT$ 10.46M
Cash Flow
Free Cash FlowNT$ -58.14MNT$ -45.81MNT$ -55.72MNT$ -94.50MNT$ -12.29M
Operating Cash FlowNT$ -50.84MNT$ -34.71MNT$ -42.15MNT$ -25.84MNT$ -4.78M
Investing Cash FlowNT$ 44.08MNT$ 108.65MNT$ -194.44MNT$ -185.40MNT$ -8.02M
Financing Cash FlowNT$ -8.21MNT$ -50.52MNT$ 248.93MNT$ 240.61MNT$ 15.28M

Currency in TWD

Merdury Biopharmaceutical Corporation Earnings and Revenue History

-80M-40M040M-4500 %-3000 %-1500 %0 %EarningsProfit Margin2019202020212022202320242025RevenueEarningsProfit Margin
Income Statement >

Merdury Biopharmaceutical Corporation Liabilities to Assets

0200M400M600M0 %120 %240 %360 %LiabilitiesLiabilities to Assets2019202020212022202320242025AssetsLiabilitiesLiabilities to Assets
Balance Sheet >

Merdury Biopharmaceutical Corporation Cash Flow

-300M-200M-100M0100M200M300M2019202020212022202320242025OperatingInvestingFinancing
Cash Flow >

Merdury Biopharmaceutical Corporation Forecast EPS vs Actual EPS

Earnings >